HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuñez, L. Articles by Oliver, J. Search for Related Content PubMed PubMed Citation Articles by Nuñez, L. Articles by Oliver, J.

Ann Thorac Surg 1984;37:84-87
© 1984 The Society of Thoracic Surgeons

---

Articles

Prevention of Thromboembolism Using Aspirin after Mitral Valve Replacement with Porcine Bioprosthesis

From the Department of Cardiac Surgery, Ciudad Sanitaria "La Paz," Autonomous University of Madrid, Madrid, Spain

Accepted for publication January 10, 1983.

The thromboembolic rate of 768 patients who were treated only with aspirin after mitral valve replacement or mitral plus aortic valve replacement with porcine bioprostheses was evaluated. We analyzed the thromboembolic rate for the whole series and for subgroups of patients categorized by atrial fibrillation, giant left atrium, left atrial thrombosis, and dosage of aspirin (1 gm daily or 0.5 gm every 48 hours). The total embolic rate was 1.4% (11/768). No patient in sinus rhythm had an embolic event. The embolic rate for patients in atrial fibrillation was 1.9% (11/583). There were no embolic events in 31 patients with a giant atrium. An embolic event occurred in 1 of 42 patients with atrial thrombosis (2.4%). Patients treated with 1 gm of aspirin daily had a 3% embolic rate (9/295) while the incidence was 0.4% (2/473) in those treated with 0.5 gm every 48 hours (p < 0.01).

Administration of aspirin after mitral valve replacement with a bioprosthesis is a very effective treatment for prevention of thromboembolism. In our experience, this treatment provides protection equal to or better than that offered by oral anticoagulants for patients in atrial fibrillation as well as for patients with a giant atrium or atrial thrombosis at operation. The dosage and timing of aspirin administration may markedly affect the result of this type of treatment. Oral anticoagulation with coumarin derivatives may not be appropriate after mitral valve replacement with a bioprosthesis, and platelet antiaggregates should be used for this purpose in the future.

This article has been cited by other articles:

				R. P. Whitlock, J. C. Sun, S. E. Fremes, F. D. Rubens, and K. H. Teoh Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest, February 1, 2012; 141(2_suppl): e576S - e600S. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 593S - 629S. [Abstract] [Full Text] [PDF]

				N. D. Desai and G. T. Christakis Bioprosthetic Aortic Valve Replacement: Stented Pericardial and Porcine Valves Card. Surg. Adult, January 1, 2008; 3(2008): 857 - 894. [Full Text]

				J. Nowell, E. Wilton, H. Markus, and M. Jahangiri Antithrombotic therapy following bioprosthetic aortic valve replacement Eur J Cardiothorac Surg, April 1, 2007; 31(4): 578 - 585. [Abstract] [Full Text] [PDF]

				D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 457S - 482S. [Abstract] [Full Text] [PDF]

				N. D. Desai and G. T. Christakis Stented Mechanical/Bioprosthetic Aortic Valve Replacement Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856. [Full Text]

				P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves Chest, January 1, 2001; 119(2009): 220S - 227S. [Full Text] [PDF]

				Y. A. Louagie, J. Jamart, P. Eucher, M. Buche, and J.-C. Schoevaerdts Mitral valve Carpentier-Edwards bioprosthetic replacement, thromboembolism, and anticoagulants Ann. Thorac. Surg., October 1, 1993; 56(4): 931 - 936. [Abstract] [PDF]

				L. H. Edmunds Jr. Thrombotic and Bleeding Complications of Prosthetic Heart Valves Ann. Thorac. Surg., October 1, 1987; 44(4): 430 - 445. [Abstract] [PDF]

				D. G. Sherman, R. G. Hart, and J. D. Easton The Secondary Prevention of Stroke in Patients With Atrial Fibrillation Arch Neurol, January 1, 1986; 43(1): 68 - 70. [Abstract] [PDF]

				Cerebral Embolism Task Force Cardiogenic Brain Embolism Arch Neurol, January 1, 1986; 43(1): 71 - 84. [Abstract] [PDF]

				T. E. David, W. I. C. Ho, and G. T. Christakis Thromboembolism in Patients with Aortic Porcine Bioprostheses Ann. Thorac. Surg., September 1, 1985; 40(3): 229 - 233. [Abstract] [PDF]